Deconstructing the contributions of heterogeneity to combination treatment of hormone sensitive breast cancer
S. Linn, J. Moore-Ott, R. Shuttleworth, W. Zhang, M. Craig, A. L. Jenner
The paper develops a mathematical model to study how tumor heterogeneity affects the response to combination therapy in hormone receptor-positive breast cancer, finding that pharmacokinetics and pharmacodynamics of fulvestrant drive treatment outcomes.
bioRxiv · May 19, 2023 · PreprintCancer Biology